This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
MOIT to Focus on Promoting Economic and Trade Cooperation in 2025
Jan 13, 2025 03:07 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Defining key tasks and accelerating the construction of new urbanization
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM
Under the Fractured Global Supply Chain, How Is United Imaging Shaping a Global "Chain"
Jan 08, 2025 06:10 PM
How AI is Driving Globalization and Transformation in Emerging Industries? | Highlights
Jan 08, 2025 05:44 PM
How Can F&B and Retail Companies Effectively Replicate Local Success Models? | Highlights
Jan 08, 2025 05:09 PM